Setmelanotide
Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients
Rhythm · Phase 1/2 · Completed · Enrollment 99
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Setmelanotide Once Daily | n/r | n/r | n/r | n/r |
| Setmelanotide Split Dose | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
Not shown
- Setmelanotide Once Daily: endpoint not reported
- Setmelanotide Split Dose: endpoint not reported
- Placebo: endpoint not reported